We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
50 hedge funds and large institutions have $37.3M invested in CASI Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
13% more capital invested
Capital invested by funds: $32.9M → $37.3M (+$4.35M)
0.01% more ownership
Funds ownership: 1.2% → 1.22% (+0.01%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
4% less funds holding
Funds holding: 52 → 50 (-2)
Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
19
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$1.19M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$655K |
| 3 |
State Street
Boston,
Massachusetts
|
+$241K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$190K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$127K |
Top Sellers
| 1 |
AA
ALPS Advisors
Denver,
Colorado
|
-$661K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$209K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$145K |
| 4 |
Renaissance Technologies
New York
|
-$120K |
| 5 |
Goldman Sachs
New York
|
-$48.7K |
